Plus Therapeutics Announces Initial Patient Treatment in REYOBIQ™ Leptomeningeal Metastases Dose Optimization Trial

Plus Therapeutics announced the treatment of the first patients in its ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re186 obisbemeda) in l...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricing
One Research Ct, Suite 450 Rockville, MD, 20850
info@pienomial.com
+91 9876543210
Copyright © 2025. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/Plus Therapeutics Announces Initial Patient Treatment in REYOBIQ™ Leptomeningeal Metastases Dose Optimization Trial